(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...
Singapore sovereign wealth fund Temasek plans to deploy another $10 billion in India over the next 2 to 3 years, focusing on ...
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Concerned Islanders and local community organizations have come together to form the Peace Coalition, to sound the alarm that ...
Family history can increase breast cancer risk, but breast health awareness and early detection remain important for every ...
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results